lunes, 21 de abril de 2014

Noninvasive prenatal testing: limitations and unanswered questions : Genetics in Medicine : Nature Publishing Group

Noninvasive prenatal testing: limitations and unanswered questions : Genetics in Medicine : Nature Publishing Group



Noninvasive prenatal testing: limitations and unanswered questions

Genetics in Medicine
 
(2014)
 
16,
 
281–285
 
doi:10.1038/gim.2013.126
Received
 
Accepted
 
Published online 

Abstract

The clinical use of noninvasive prenatal testing to screen high-risk patients for fetal aneuploidy is becoming increasingly common. Initial studies have demonstrated high sensitivity and specificity, and there is hope that these tests will result in a reduction of invasive diagnostic procedures as well as their associated risks. Guidelines on the use of this testing in clinical practice have been published; however, data on actual test performance in a clinical setting are lacking, and there are no guidelines on quality control and assurance. The different noninvasive prenatal tests employ complex methodologies, which may be challenging for health-care providers to understand and utilize in counseling patients, particularly as the field continues to evolve. How these new tests should be integrated into current screening programs and their effect on health-care costs remain uncertain.
Genet Med 2014:16(4):281–285.
View full text

Keywords:

 
aneuploidy; cell-free DNA; genetic counseling; noninvasive prenatal screening; noninvasive prenatal testing

References

  1. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132–1139.
  2. Dennis Lo Y, Chiu RW. Plasma nucleic acid analysis by massively parallel sequencing: pathological insights and diagnostic implications. J Pathol 2011;225:318–323.
  3. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA2008;105:16266–16271.
  4. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3–9.
  5. Smith M, Visootsak J. Noninvasive screening tools for Down syndrome: a review. Int J Womens Health 2013;5:125–131.
  6. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32:1233–1241.
  7. Malone FD, Canick JA, Ball RH, et al.; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005;353:2001–2011.
  8. Chen EZ, Chiu RW, Sun H, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS ONE 2011;6:e21791.
  9. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol2012;119:890–901.
  10. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med2011;13:913–920.
  11. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study.Genet Med 2012;14:296–305.
  12. ACOG Committee Opinion 545. Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120:1532–1534.
  13. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns 2013;22:291–295.
  14. Benn P, Borrell A, Crossley J, et al.; International Society for Prenatal Diagnosis. Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenat Diagn 2011;31:519–522.
  15. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395–398.
  16. Fairbrother G, Johnson S, Musci TJ, Song K. Clinical experience of noninvasive prenatal testing with cell-free DNA for fetal trisomies 21, 18, and 13, in a general screening population.Prenat Diagn 2013;33:580–583.
  17. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol2012;207:374.e1–374.e6.
  18. Choi H, Lau TK, Jiang FM, et al. Fetal aneuploidy screening by maternal plasma DNA sequencing: ‘false positive’ due to confined placental mosaicism. Prenat Diagn2013;33:198–200.
  19. Pan M, Li FT, Li Y, et al. Discordant results between fetal karyotyping and non-invasive prenatal testing by maternal plasma sequencing in a case of uniparental disomy 21 due to trisomic rescue. Prenat Diagn 2013;33:598–601.
  20. Ledbetter DH, Zachary JM, Simpson L, et al. Cytogenetic results from the US Collaborative Study on CVS. Prenat Diagn 1992;12:317–345.
  21. Stetten G, Escallon CS, South ST, McMichael JL, Saul DO, Blakemore KJ. Reevaluating confined placental mosaicism. Am J Med Genet A 2004;131:232–239.
  22. Masuzaki H, Miura K, Yoshiura KI, Yoshimura S, Niikawa N, Ishimaru T. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet 2004;41:289–292.
  23. Kalousek DK, Vekemans M. Confined placental mosaicism. J Med Genet 1996;33:529–533.
  24. Artan S, Basaran N, Hassa H, et al. Confined placental mosaicism in term placentae: analysis of 125 cases. Prenat Diagn 1995;15:1135–1142.
  25. Jensen TJ, Dzakula Z, Deciu C, van den Boom D, Ehrich M. Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem2012;58:1148–1151.
  26. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ2011;342:c7401.
  27. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol2011;204:205.e1–205.11.
  28. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1–137.e8.
  29. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics.Ultrasound Obstet Gynecol 2013;41:26–32.
  30. Norton ME, Rose NC, Benn P. Noninvasive prenatal testing for fetal aneuploidy clinical assessment and a plea for restraint. Obstet Gyencol 2013;121(4):847–850.
  31. Weaver C. Tough calls on prenatal tests. The Wall Street Journal 2013:B1.
Download references

Author information

Affiliations

  1. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Madigan Army Medical Center, Tacoma, Washington, USA

    • Monica A. Lutgendorf,
      •  
    • Katie A. Stoll,
      •  
    • Dana M. Knutzen &
      •  
    • Lisa M. Foglia

  2. military service member

    • Monica A. Lutgendorf &
      •  
    • Lisa M. Foglia

Corresponding author

Correspondence to: 
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)